With its move to MIT’s Volpe Center in Kendall Square, the drugmaker is consolidating its local footprint from three ...

Biogen has signed a 15-year lease for approximately 580,000-square-feet of office and research and development space as part of the Kendall Common development project. The lease agreement is with a ...

Cambridge-based biotechnology company Biogen Inc. announced Monday that it will move its global headquarters to a new ...

The big biotech signed a 15-year lease for approximately 580,000-square-feet of space in “Kendall Commons,” a development ...

Biogen's new management is diversifying its product portfolio and optimizing costs, but faces significant risks from market share loss and generic competition. The fair valuation of Biogen shares ...

The biotech company plans to move into the new development in 2028, consolidating other leased and owned spaces in the ...

Biogen Inc. (NASDAQ: BIIB) has unveiled plans for its new global headquarters in Cambridge, located across the Charles River from Boston. The biotechnology company has selected Kendall Common, located ...

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...

The molecular targets of existing antibacterial agents are limited. Given the rise of antibiotic resistance, it is vital to identify novel bacterial processes that can be therapeutically targeted.

Biogen exits biosimilar JV with Samsung, raising $2.3bn News The South Korean firm just agreed to buy Biogen out of their biosimilar joint venture – Samsung Bioepis – for $2.3 billion.